Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Multiple Myeloma 61Lymphoma, Follicular 16Recurrence 13Lymphoma, Non-Hodgkin 12Lymphoma, Mantle-Cell 12Lymphoma 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, B-Cell, Marginal Zone 9Lymphoma, Large B-Cell, Diffuse 8Leukemia, Lymphocytic, Chronic, B-Cell 8Waldenstrom Macroglobulinemia 7Neoplasms 7Neoplasms, Plasma Cell 6Lymphoma, Large-Cell, Anaplastic 5Leukemia, Myeloid, Acute 5Immunoblastic Lymphadenopathy 5Lymphoma, T-Cell, Cutaneous 4Hodgkin Disease 4Carcinoma, Non-Small-Cell Lung 4Sezary Syndrome 3Prostatic Neoplasms 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Myelodysplastic Syndromes 3Mycosis Fungoides 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, B-Cell 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia, Erythroblastic, Acute 3Leukemia 3

Interventions

Cyclophosphamide 3Busulfan 3Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Methotrexate 2Filgrastim 2Arsenic Trioxide 2tamibarotene 1fludarabine phosphate 1Tretinoin 1Mycophenolic Acid 1Idarubicin 1Clofarabine 1Bortezomib 1Antilymphocyte Serum 1Alemtuzumab 1AEG 35156 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Promyelocytic, Acute × Bortezomib × Clear all
NCT01465386 2017-04-04

Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

Fred Hutchinson Cancer Center

Phase 2 Terminated
6 enrolled 8 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡